Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

ALG-000184

Generic Name: ALG-000184

Overview

No overview information available.

Background

No background information available.

Indication

No indication information available.

Associated Conditions

No associated conditions information available.

Clinical Trials

A Study Evaluating the Efficacy and Safety of ALG-000184 Compared With Tenofovir Disoproxil Fumarate in Untreated HBeAg-Positive and HBeAg- Negative Adult Subjects With Chronic Hepatitis B (B-SUPREME)

Phase 2

Not yet recruiting

Posted: 2025/05/09

Sponsor:Aligos Therapeutics

ID:NCT06963710

A Multi-part Study of ALG-000184 to Evaluate Safety, Tolerability, Pharmacokinetics and Drug-drug Interaction Potential After Single and Multiple Doses in Healthy Volunteers

Phase 1

Active, not recruiting

Posted: 2024/11/04

Sponsor:Aligos Therapeutics

ID:NCT06672900

A Study of ALG-000184 Drug to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics After Single and Multiple Doses in Healthy Volunteers and CHB Subjects

Phase 1

Recruiting

Posted: 2020/09/02

Sponsor:Aligos Therapeutics

ID:NCT04536337

FDA Approved Products

No FDA products found for this drug

Singapore Approved Products

No Singapore products found for this drug

Related News

Aligos Therapeutics Reports Promising 96-Week Data for HBV Treatment and Positive Results in MASH Study at APASL 2025

2 months ago

Aligos Therapeutics presented 96-week data showing ALG-000184 achieved significant HBV DNA suppression in both HBeAg-positive and HBeAg-negative patients, positioning it as a potential first-line therapy for chronic hepatitis B.

Aligos Therapeutics Secures $105M Financing to Advance Hepatitis B Drug Development

4 months ago

Aligos Therapeutics has secured a $105 million private placement financing led by a life sciences investment firm, strengthening its position to advance ALG-000184 into Phase 2 clinical trials for chronic hepatitis B.

Aligos Therapeutics' ALG-000184 Receives FDA IND Clearance for Hepatitis B

7 months ago

Aligos Therapeutics received FDA clearance for its Investigational New Drug (IND) application for ALG-000184, a capsid assembly modulator for chronic hepatitis B (CHB).

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Home Terms & Conditions Privacy Policy